Navigation Links
YMed, Inc. Successfully Completes First Clinical Cases With Innovative VascuTraK(TM) II PTA Dilatation Catheter
Date:12/10/2007

SAN DIEGO, Dec. 10 /PRNewswire/ -- YMed, Inc. announced today that it has successfully completed its first U.S. cases with its proprietary VascuTraK(TM) II PTA Dilatation Catheter. The VascuTraK(TM) II PTA Catheter is a unique 5F compatible, single operator rapid exchange system.

YMed's VascuTraK(TM) II catheter is designed and indicated for vascular intervention of a wide range of peripheral arteries including the treatment of obstructive lesions of native or synthetic arteriovenous dialysis fistulae.

"The VascuTraK(TM) II catheter is an important advancement in technology for the treatment of patients with peripheral vascular disease (PVD), especially below the knee where amputation risks are the greatest," says Dr. Rajesh Dave, Chairman, Endovascular Medicine, Harrisburg Hospital, Harrisburg, PA. Dr. Dave performed the initial clinical cases with commercially available VascuTraK(TM) II catheters. He noted that in some lesion subsets, including calcified lesions involving the popliteal artery, the VascuTraK(TM) II catheter was sufficient to complete the intervention without adjunctive devices that may increase restenois or require further intervention.

YMed plans to initiate U.S. Sales with a broad range of VascuTraK(TM) II PTA dilatation catheters during Q1 2008, says Richard Cooper, Vice President Sales & Marketing, YMed, Inc. "The VascuTraK(TM) II is the first PTA dilatation catheter to combine the features of plaque modification and longer balloon lengths," Mr. Cooper added. Balloon diameters range from 2.0 mm to 4.0 mm in 0.5 mm increments with balloon lengths of 20 mm to 120 mm.

YMed, Inc. is a privately held Corporation established in 2004. The company was founded and is managed by a highly experienced, multinational team of medical, engineering and business professionals from within the cardio and peripheral vascular industry. This team develops, manufactures and markets innovative products for vascular intervention provi
'/>"/>

SOURCE YMed, Inc.
Copyright©2007 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2

Related medicine technology :

1. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
2. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
3. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
4. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
5. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
6. QuatRx Completes Patient Enrollment in Phase 3 Study of Ophena(TM) in Women with Postmenopausal Vaginal Syndrome
7. CryoCor Completes Enrollment of Pivotal Clinical Study for Atrial Fibrillation
8. Anesiva Completes Enrollment in Phase 3 Clinical Trial of Zingo(TM) to Treat Pain Associated With Venous Access Procedures in Adults
9. Human Genome Sciences Completes Enrollment of First Phase 3 Albuferon(R) Trial Ahead of Schedule
10. Cadence Pharmaceuticals Completes Enrollment of Pivotal Phase III Trial for Intravenous Acetaminophen Ahead of Schedule
11. TorreyPines Therapeutics Completes Phase I Multiple Dose Clinical Trial of NGX267, a Selective M1 Agonist for the Potential Treatment of Cognitive Impairment Associated with Schizophrenia

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/25/2009)...wswire/--Reportlinker.comannouncesthatanewmarketre...anasalDrugDelivery-USMarketTrends&Analysis ht...-Delivery---US-Market-Trends--Analysis.html ,,...pansionoftherapeuticapplicationsfromthedeliveryofc...temictherapeuticdrugs.Thefutureofthetechnologyhing...
(Date:11/25/2009)...SYDNEY,Nov.25/PRNewswire-FirstCall/--HeartWareInte...vatorandprovideroflessinvasive,miniaturizedcircula...ofadvancedheartfailure,todayannouncedthatitissched...erJaffrayHealthCareConferenceat8:00amESTonWednesda...orkPalaceHotel,December1-2. ,, Alivewebcastofth...
(Date:11/24/2009).../PRNewswire-Asia/--ChindexInternational,Inc.,("Chi...roviderofWestern,healthcareproductsandservicesinth...panywillattendthe21stAnnualPiperJaffray,"Unplugged...he,NewYorkPalaceHotel. , Managementiscurrentl...,2009,andholdone-on-onemeetingsthroughouttheday.Aw...
Breaking Medicine Technology:Reportlinker Adds Intranasal Drug Delivery - US Market Trends & Analysis 2Reportlinker Adds Intranasal Drug Delivery - US Market Trends & Analysis 3Reportlinker Adds Intranasal Drug Delivery - US Market Trends & Analysis 4Reportlinker Adds Intranasal Drug Delivery - US Market Trends & Analysis 5Chindex International to Present at Piper Jaffray Health Care Conference 2Remarks As Prepared for Delivery by Attorney General Eric Holder at the Heat Press Conference on Detroit Takedown 49965 1Remarks As Prepared for Delivery by Attorney General Eric Holder at the Heat Press Conference on Detroit Takedown 49965 2Remarks As Prepared for Delivery by Attorney General Eric Holder at the Heat Press Conference on Detroit Takedown 49965 3AEterna Zentaris Receives US 2410 Million from Institutional Investors 12773 1AEterna Zentaris Receives US 2410 Million from Institutional Investors 12773 2AEterna Zentaris Receives US 2410 Million from Institutional Investors 12773 3Commonwealth Fund Case Study Points to Continuous Innovation at Group Health Cooperative 4643 1Commonwealth Fund Case Study Points to Continuous Innovation at Group Health Cooperative 4643 2Commonwealth Fund Case Study Points to Continuous Innovation at Group Health Cooperative 4643 3
... 22 Immtech Pharmaceuticals,Inc. (Amex: IMM ) to...ew,drug discovery programs targeting Hepatitis C, ..., and will discontinue all development programs fo...igational therapy. The,decision was made in respon...identified in a cohort of volunteers in a safety s...
...l antiplatelet agent submitted for treatment of pa...ed with percutaneous coronary ...b. 21 Daiichi,Sankyo Company, Limited (TSE: 4568)...ounced that the U.S. Food and Drug Administration ...the New Drug Application for prasugrel,for patient...
Other Medicine Technology:Immtech Focusing on Other Infectious Disease Programs Following Discontinuation of Development of Pafuramidine 2Immtech Focusing on Other Infectious Disease Programs Following Discontinuation of Development of Pafuramidine 3Immtech Focusing on Other Infectious Disease Programs Following Discontinuation of Development of Pafuramidine 4FDA Grants Priority Review for Daiichi Sankyo, Lilly Drug, prasugrel 2FDA Grants Priority Review for Daiichi Sankyo, Lilly Drug, prasugrel 3
(Date:11/26/2009)... In the next 25 years, the number of Americans li...from 23.7 million in 2009 to 44.1 million in 2034....lmost triple, rising from $113 billion to $336 bil...besity, researchers based at the University of Chi...e . , The number of those with diabetes covered ...
(Date:11/26/2009)... Dr. David Kim of the Liv...oss surgery in Dallas , is one of a growing number...r social networking sites to connect with individu...atment to fight morbid obesity. Dr. Kim is utilizi...nformation about his practice with the community. ...
(Date:11/25/2009)...,, KANSASCITY,Mo.,Nov.25/PRNewswire/--TheBart...on,slargestmedicalcliniconDec.9-10,whenKansasCityh...uredpeople. ,, "Thisfreecliniceventhasthepotent...daysinsteadofjustoneandbeheldonweekdaysinsteadofov...CityFreeHealthClinicandpresidentoftheNationalAssoc...
(Date:11/25/2009)...,, SILVERSPRING,Md.,Nov.25/PRNewswire-USNewsw...DA,sCenterforDrugEvaluationandResearch,titled"ADif..."appearsintheNov.26,2009issueofTheNewEnglandJourna...gi-bin/prnh/20090824/FDALOGO ) ,, Inthearticle,...accesstopainmedicationforthosewhoneeditandmanaging...
(Date:11/25/2009)... Researchers have found evidence of a statistical...xifen among patients whose estrogen receptor (ER)-... of ER-alpha; at serine-118 (ER-alpha S118-P), acc...ovember 25 in the Journal of the National Cancer ...omas are resistant to tamoxifen. Preclinical studi...
Breaking Medicine News(10 mins):Health News:Diabetes cases to double and costs to triple by 2034 2Health News:Diabetes cases to double and costs to triple by 2034 3Health News:Dallas Texas Weight Loss Surgeon Using Social Media To Reach Out to Patients 2Health News:Dallas Texas Weight Loss Surgeon Using Social Media To Reach Out to Patients 3Health News:Kansas City Prepares for Largest Free Health Clinic 2
...de this summer when the U.S. Food and Drug Adminis...t cervical cancer//. The vaccine was given the gre...tect against human papillomavirus (HPV), a sexuall...the Society for Women’s Health Research and chair ...
...istributed to cope with a major influenza pandemic...e of the Medical Journal of Australia. // As...Sydney GP Dr Nick Collins and colleagues outlined ...es are recognised in some rural and outer metropol...
...re attending to babies born to drug-addicted mothe... before the babies are discharged from the hospita... treatment for drug addictions at the hospital ann...es in the special care nursery because they show s...
...ene that could possibly be the reason behind breas...taking a turn for the worse. // Melbourne sci...n mice discovered that a gene known as body morpho...ich was capable of offsetting breast tumors from b...
...rs, like hemophilia, is being used to control blee... The drug Recombinant Activated Factor VIII has ...ions in non-hemophiliacs. It can cause heart attac...d loss. Jawed Fareed an expert in blood clotti...
...al Devon and Exeter Hospital postulates that the f...//Mothers seem to determine how plump babies final... the researchers say that results derived so far, ...y, babies of mothers who are plump were seen to ha...
Other Medicine News:Health News:Triumphs and Hurdles for the New HPV Vaccine 2Health News:Triumphs and Hurdles for the New HPV Vaccine 3
...my System features an advanced design, solid state...ell as many years of clinical experience, has esta...he placement of discrete burns on the pigment epit...effect at the target tissue with the least possibl...
EL401 Manual Washer
SureSigns C1 Compact Patient Monitor
MP30
Medicine Products: